Community Oncology Alliance

OneOncology and Coastal Cancer Center Purchase Two Radiation Oncology Centers and Partner with Three South Carolina Radiation Oncologists in Myrtle Beach and Conway

Retrieved on: 
Tuesday, February 6, 2024

NASHVILLE, Tenn. and MYRTLE BEACH, S.C., Feb. 6, 2024 /PRNewswire/ -- OneOncology, the fastest-growing national platform for independent oncology practices, and its South Carolina-based partner, Coastal Cancer Center, announced they have purchased two radiation oncology centers located in Myrtle Beach and Conway, South Carolina from GenesisCare. As part of the transaction, three radiation oncologists and 40 employees will join Coastal Cancer Center and continue caring for patients at both locations.  

Key Points: 
  • NASHVILLE, Tenn. and MYRTLE BEACH, S.C., Feb. 6, 2024 /PRNewswire/ -- OneOncology, the fastest-growing national platform for independent oncology practices, and its South Carolina-based partner, Coastal Cancer Center, announced they have purchased two radiation oncology centers located in Myrtle Beach and Conway, South Carolina from GenesisCare.
  • As part of the transaction, three radiation oncologists and 40 employees will join Coastal Cancer Center and continue caring for patients at both locations.
  • OneOncology and Coastal Cancer Center are purchasing two radiation oncology centers located in Myrtle Beach and Conway.
  • The Myrtle Beach radiation oncology center is located at 4708 Oleander Drive and the Conway center is at 8059 Myrtle Trace Drive.

PatientPoint Welcomes Jeff Vacirca, MD, FACP, and Amy Grogg, PharmD, to Board of Directors

Retrieved on: 
Wednesday, December 13, 2023

CINCINNATI, Dec. 13, 2023 /PRNewswire/ -- PatientPoint® today announced the addition of Jeffrey Vacirca, MD, FACP, and Amy Grogg, PharmD, to its board of directors. Dr. Vacirca will serve as an independent board member while Ms. Grogg will serve as a board advisor. Taken together, Dr. Vacirca and Ms. Grogg bring deep care delivery and life science commercialization expertise to PatientPoint's board.

Key Points: 
  • CINCINNATI, Dec. 13, 2023 /PRNewswire/ -- PatientPoint® today announced the addition of Jeffrey Vacirca, MD, FACP, and Amy Grogg, PharmD, to its board of directors.
  • Dr. Vacirca will serve as an independent board member while Ms. Grogg will serve as a board advisor.
  • Taken together, Dr. Vacirca and Ms. Grogg bring deep care delivery and life science commercialization expertise to PatientPoint's board.
  • Ms. Grogg brings nearly 30 years of pharmaceutical commercialization experience to the PatientPoint board.

American Oncology Network Leaders Slated To Speak at Association for Value-Based Cancer Care 2023 Summit

Retrieved on: 
Wednesday, October 18, 2023

“The cancer fight is everyone’s responsibility and so much can be learned by looking to our partners throughout the industry and taking note of best practices.

Key Points: 
  • “The cancer fight is everyone’s responsibility and so much can be learned by looking to our partners throughout the industry and taking note of best practices.
  • Filled with various educational sessions, attendees will gain insightful and relevant information that can be implemented in clinics and institutions.
  • “We are honored to have representatives from AON speaking at this prestigious event,” said Todd Schonherz, AON’s chief executive officer.
  • “To us as an organization, it is important that we consistently work toward being at the forefront of cancer care.

OneOncology and Practice Partners to Present 11 Abstracts at ASCO Quality Care Symposium

Retrieved on: 
Tuesday, October 17, 2023

NASHVILLE, Tenn., Oct. 17, 2023 /PRNewswire/ -- OneOncology, the national platform for independent oncology practices, announced today that researchers at OneOncology and its partner practices will present 11 abstracts at the upcoming ASCO Quality Care Symposium October 27-28.

Key Points: 
  • Researchers to Present on Genetic Testing, Precision Medicine, Care Delivery & Physician Workforce Research
    NASHVILLE, Tenn., Oct. 17, 2023 /PRNewswire/ -- OneOncology, the national platform for independent oncology practices, announced today that researchers at OneOncology and its partner practices will present 11 abstracts at the upcoming ASCO Quality Care Symposium October 27-28.
  • Neha Jain, Ph.D., OneOncology's Senior Director of Precision Medicine, will present "Provider Messaging for Precision Treatment (ProMPT): A Notification Pilot to Inform Actionable Genomic Findings."
  • The next iteration of ProMPT will use OneOncology's proprietary analytics platform to incorporate genomic information into our physicians' workstream.
  • Tennessee Oncology researchers will present six abstracts addressing topics including clinical innovation, care delivery, OCM learnings and implications for value-based care, automating behavior economics and analytics to improve palliative care, and scaling oncology disease expertise in urban and rural clinics.

Prevent Cancer Foundation raises more than $2 million for cancer prevention and early detection at annual Gala

Retrieved on: 
Monday, October 2, 2023

Washington, D.C., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Jordanian royalty graced the stage at the Prevent Cancer Foundation’s 29th Annual Gala.

Key Points: 
  • Washington, D.C., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Jordanian royalty graced the stage at the Prevent Cancer Foundation’s 29th Annual Gala.
  • Her Royal Highness, Princess Ghida Talal of Jordan and Her Excellency, Ambassador Dina Kawar attended the event appropriately themed Jordan: Pillar of Wonder, continuing with a Gala tradition of honoring a country that shares the Foundation’s commitment to fighting cancer.
  • With nearly 1,000 guests in attendance at the National Building Museum in Washington, D.C., the Gala brought in more than $2 million for cancer prevention and early detection.
  • Thank you to the 2023 Prevent Cancer Gala top sponsors:

National Association of Specialty Pharmacy (NASP) Welcomes New Board Chairman, New Board Members, and Congratulates Award Winners at its Record-Breaking 2023 Annual Meeting & Expo

Retrieved on: 
Thursday, September 21, 2023

He also thanked the board members who are concluding their terms for their long-standing service to NASP.

Key Points: 
  • He also thanked the board members who are concluding their terms for their long-standing service to NASP.
  • Their unwavering dedication shaped the future of not only NASP but also the specialty pharmacy industry,” said Mr. Skiermont.
  • In addition to celebrating new board members, a total of eight industry award winners, four poster award winners, and three scholarship recipients were announced.
  • The new board members, Industry Award winners, Poster award winners, and Scholarship Award winners were all recognized during the meeting to a record audience of more than 1,600 attendees.

Biofidelity announces the commercial launch of ASPYRE-Lung in the US

Retrieved on: 
Tuesday, September 5, 2023

CAMBRIDGE, England and RESEARCH TRIANGLE PARK, N.C., Sept. 5, 2023 /PRNewswire/ -- Biofidelity, a revolutionary genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world, today announced the commercial launch of ASPYRE®-Lung in the US.

Key Points: 
  • New assay provides rapid access to guideline recommended biomarkers within days of a non-small cell lung cancer diagnosis.
  • CAMBRIDGE, England and RESEARCH TRIANGLE PARK, N.C., Sept. 5, 2023 /PRNewswire/ -- Biofidelity, a revolutionary genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world, today announced the commercial launch of ASPYRE®-Lung in the US.
  • "Today's launch of ASPYRE-Lung reflects Biofidelity's mission to bring the benefits of precision medicine to millions of patients around the world."
  • "It's time we overcome the complexity and inefficiency of testing that is limiting the potential survival advantage of precision medicine."

Community Oncology Alliance Selects The Doctors Company as Exclusive Medical Malpractice Insurance Partner

Retrieved on: 
Wednesday, August 23, 2023

NAPA, Calif., Aug. 23, 2023 /PRNewswire/ -- The Community Oncology Alliance (COA) has chosen The Doctors Company, part of TDC Group, as the exclusively endorsed medical malpractice insurer for its members.

Key Points: 
  • NAPA, Calif., Aug. 23, 2023 /PRNewswire/ -- The Community Oncology Alliance (COA) has chosen The Doctors Company, part of TDC Group, as the exclusively endorsed medical malpractice insurer for its members.
  • COA is a nonprofit organization dedicated to advocating for community oncology practices and, most importantly, the patients they serve.
  • For more than 20 years, COA has been the only organization dedicated solely to community oncology, where the majority of Americans with cancer are treated.
  • COA members can now benefit from a number of offerings from The Doctors Company, including competitive rates and discounts for medical malpractice insurance.

Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction

Retrieved on: 
Tuesday, August 1, 2023

LAKE FOREST, Ill., July 31, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc. (“Spectrum”) (Nasdaq: SPPI), a biopharmaceutical company focused on novel and targeted oncology.

Key Points: 
  • LAKE FOREST, Ill., July 31, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc. (“Spectrum”) (Nasdaq: SPPI), a biopharmaceutical company focused on novel and targeted oncology.
  • Assertio intends to provide updated guidance for the combined business as part of its second quarter results call on August 3.
  • He also serves on the board of directors of Annexus Health, Spectrum Pharmaceuticals, OneOncology, and the American Red Cross of Greater New York.
  • Dr. Vacirca also received the Theodore Roosevelt Award for outstanding dedication to patient care and was named Newsday's Top Doctor.

Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)

Retrieved on: 
Wednesday, May 31, 2023

The abstract will be published at the 2023 American Society of Clinical Oncology (ASCO) annual meeting to take place June 2-6 in Chicago, IL.

Key Points: 
  • The abstract will be published at the 2023 American Society of Clinical Oncology (ASCO) annual meeting to take place June 2-6 in Chicago, IL.
  • The trial leveraged the National Cancer Institute (NCI) Community Oncology Research Program ( NCORP ).
  • "These efficacy results from a sham-controlled RCT of Quell in CIPN are exciting and consistent with an earlier published open-label study .
  • The use of Quell for chemotherapy induced peripheral neuropathy is investigational and has not been cleared or approved by the FDA.